1. Prognostic effect of lncRNA SNHG7 on cancer outcome: a meta and bioinformatic analysis
- Author
-
Qingwu Tian, Shifeng Huang, Yunyuan Zhang, Xian Chen, Qing Wang, Qian Dong, and Hongmei Wu
- Subjects
Oncology ,Cancer Research ,medicine.medical_specialty ,Outcome (game theory) ,SNHG7 ,Predictive Value of Tests ,Internal medicine ,Neoplasms ,Genetics ,medicine ,Biomarkers, Tumor ,Humans ,prognostic biomarker ,RC254-282 ,Cancer ,Proportional Hazards Models ,business.industry ,Research ,Carcinoma ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,Computational Biology ,medicine.disease ,Prognosis ,meta-analysis ,Lymphatic Metastasis ,RNA, Long Noncoding ,business - Abstract
Background New evidence from clinical and fundamental researches suggests that SNHG7 is involved in the occurrence and development of carcinomas. And the increased levels of SNHG7 are associated with poor prognosis in various kinds of tumors. However, the small sample size was the limitation for the prognostic value of SNHG7 in clinical application. The aim of the present meta-analysis was to conduct a qualitative analysis to explore the prognostic value of SNHG7 in various cancers. Methods Articles related to the SNHG7 as a prognostic biomarker for cancer patients, were comprehensive searched in several electronic databases. The enrolled articles were qualified via the preferred reporting items for systematic reviews and meta-analysis of observational studies in epidemiology checklists. Additionally, an online database based on The Cancer Genome Atlas (TCGA) was further used to validate our results. Results We analyzed 2418 cancer patients that met the specified criteria. The present research indicated that an elevated SNHG7 expression level was significantly associated with unfavorable overall survival (OS) (HR = 2.45, 95% CI: 2.12–2.85, p p p p p p Conclusions The present analysis suggests that elevated SNHG7 is significantly associated with unfavorable OS, tumor progression, LNM and DM in various carcinomas, and may be served as a promising biomarker to guide therapy for cancer patients.
- Published
- 2022